Authoritative reporting on medicine, public health, research and the policy and science shaping patient care.
Gedatolisib, Celcuity's PI3K/mTOR inhibitor, faces a July 17, 2026 FDA decision that could deliver the first targeted therapy for HR-positive, PIK3CA wild-type advanced breast cancer patients with no options after CDK4/6 and hormone therapy.
Vera Therapeutics faces a July 7, 2026 FDA deadline on atacicept, a twice-monthly injection that could become the first dual BAFF and APRIL biologic approved for IgA nephropathy, a leading cause of kidney failure in young adults.
2.4 million acres had burned across the U.S. by early June 2026, and smoke from roughly 200 Canadian wildfires has since pushed air quality to unhealthy levels in at least 14 Midwest and Northeast states, triggering health advisories for vulnerable residents.
Foundayo, Eli Lilly's oral GLP-1 pill approved by the FDA on April 1, 2026, becomes available to eligible Medicare beneficiaries for a flat $50 monthly copay starting July 1 under a federal demonstration program running through 2027.
5,500 additional American children become newly eligible for a one-time cure after the FDA expanded Vertex's CRISPR therapy Casgevy to patients as young as 2 with sickle cell disease on July 1, 2026.
160 million Americans woke to heat alerts on July 4th as a record-shattering heat dome pushed indices past 110 degrees, breaking a 128-year-old mark in Washington and forcing Philadelphia to cancel its parade.
48 confirmed West Nile cases across 23 states and four Arizona deaths mark the earliest severe start to a season in over two decades, CDC data through June 30, 2026 shows, just as July 4 crowds head outdoors.
2,170 confirmed measles cases across 41 states through July 2, 2026 have nearly matched all of 2025, pushing the United States toward losing the elimination status it has held since 2000 when PAHO rules in November.
3.8 million Medicare beneficiaries can now obtain Wegovy, Zepbound, or the new pill Foundayo for weight loss at a flat $50 monthly copay under a Bridge program that began July 1, 2026, the first obesity-drug coverage in over two decades.
Reporting from adjacent desks, selected to broaden the view beyond the Health section.
Blackstone's sandwich chain heads to the NYSE at a targeted $12 billion valuation, with a prospectus detailing payments to the founder's relatives before public investors arrive.
Sam Altman pitches Trump officials on donating 5% of OpenAI equity to a citizen dividend fund, a move with heavy consequences for the company's eventual IPO.
The EU Court of Justice has rejected Google's last appeal against its 4.1 billion euro Android penalty, cementing a precedent that will shape platform enforcement for years.
